Free Trial

Regeneron Pharmaceuticals (REGN) Earnings Date, Estimates & Call Transcripts

Regeneron Pharmaceuticals logo
$701.85 -6.40 (-0.90%)
(As of 12/20/2024 05:51 PM ET)
Get Regeneron Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regeneron Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

REGN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

REGN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Regeneron Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242$7.48$8.05$7.77
Q2 20242$9.20$9.67$9.44
Q3 20242$9.80$11.42$10.61
Q4 20242$7.72$10.57$9.15
FY 20248$34.20$39.71$36.96

Regeneron Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/1/2024Q2 2024$8.93$11.56+$2.63$7.79$3.38B$3.55B
5/2/2024Q1 2024$8.46$7.97 -$0.49$9.67$3.19B$3.15B
2/2/2024Q4 2023$10.73$11.86+$1.13$10.17$3.29B$3.43B
11/2/2023Q3 2023$9.39$10.17+$0.78$11.45$3.23B$3.36B
8/3/2023Q2 2023$8.48$10.24+$1.76$9.08$3.02B$3.16B
5/4/2023Q1 2023$7.71$8.44+$0.73$9.71$2.92B$3.16B
2/3/2023Q4 2022$8.18$12.56+$4.38$11.42$3.11B$3.41B

Regeneron Pharmaceuticals Earnings - Frequently Asked Questions

Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded annual revenue of $13.85 billion.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded net income of $3.95 billion. REGN has generated $40.41 earnings per share over the last four quarters.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a trailing price-to-earnings ratio of 17.37 and a forward price-to-earnings ratio of 18.54. The price/earnings-to-growth ratio is 2.19.

Regeneron Pharmaceuticals's earnings are expected to grow from $37.85 per share to $38.03 per share in the next year, which is a 0.48% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:REGN) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners